Ben Boursi1,2,3, Brian Finkelman4, Bruce J Giantonio5, Kevin Haynes1, Anil K Rustgi1,6, Andrew D Rhim7, Ronac Mamtani1,2, Yu-Xiao Yang1. 1. Department of Medicine, Perelman School of Medicine. 2. Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 3. School of Medicine, Tel-Aviv University, Tel-Aviv, Israel. 4. Department of Pathology, Feinberg School of Medicine, Northwestern University. 5. Department of Medicine, Harvard Medical School and Massachusetts General Hospital. 6. Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center. 7. Department of Gastroenterology, Hepatology and Nutrition, Sheikh Ahmed Bin Zayed Al Nahyan Center for Pancreatic Cancer Research, University of Texas M.D. Anderson Cancer Center.
Abstract
BACKGROUND: Early detection of pancreatic ductal adenocarcinoma (PDA) may improve survival. We previously developed a clinical prediction model among patients with new-onset diabetes to help identify PDAs 6 months prior to the clinical diagnosis of the cancer. We developed and internally validated a new model to predict PDA risk among those newly diagnosed with impaired fasting glucose (IFG). METHODS: We conducted a retrospective cohort study in The Health Improvement Network (THIN) (1995-2013) from the UK. Eligible study patients had newly diagnosed IFG during follow-up in THIN. The outcome was incident PDA diagnosed within 3 years of IFG diagnosis. Candidate predictors were factors associated with PDA, glucose metabolism or both. RESULTS: Among the 138 232 eligible patients with initial IFG diagnosis, 245 (0.2%) were diagnosed with PDA within 3 years. The median time from IFG diagnosis to clinical PDA diagnosis was 326 days (IQR 120-588). The final prediction model included age, BMI, proton pump inhibitor use, total cholesterol, low-density lipoprotein, alanine aminotransferase and alkaline phosphatase. The model achieved good discrimination [area under the curve 0.71 (95% CI, 0.67-0.75)] and calibration (Hosmer and Lemeshow goodness-of-fit test P > 0.05 in 17 of the 20 imputed data sets) with optimism of 0.0012662 (95% CI, -0.00932 to 0.0108771). CONCLUSIONS: We developed and internally validated a sequential PDA prediction model based on clinical information routinely available at the initial appearance of IFG. If externally validated, this model could significantly extend our ability to detect PDAs at an earlier stage.
BACKGROUND: Early detection of pancreatic ductal adenocarcinoma (PDA) may improve survival. We previously developed a clinical prediction model among patients with new-onset diabetes to help identify PDAs 6 months prior to the clinical diagnosis of the cancer. We developed and internally validated a new model to predict PDA risk among those newly diagnosed with impaired fasting glucose (IFG). METHODS: We conducted a retrospective cohort study in The Health Improvement Network (THIN) (1995-2013) from the UK. Eligible study patients had newly diagnosed IFG during follow-up in THIN. The outcome was incident PDA diagnosed within 3 years of IFG diagnosis. Candidate predictors were factors associated with PDA, glucose metabolism or both. RESULTS: Among the 138 232 eligible patients with initial IFG diagnosis, 245 (0.2%) were diagnosed with PDA within 3 years. The median time from IFG diagnosis to clinical PDA diagnosis was 326 days (IQR 120-588). The final prediction model included age, BMI, proton pump inhibitor use, total cholesterol, low-density lipoprotein, alanine aminotransferase and alkaline phosphatase. The model achieved good discrimination [area under the curve 0.71 (95% CI, 0.67-0.75)] and calibration (Hosmer and Lemeshow goodness-of-fit test P > 0.05 in 17 of the 20 imputed data sets) with optimism of 0.0012662 (95% CI, -0.00932 to 0.0108771). CONCLUSIONS: We developed and internally validated a sequential PDA prediction model based on clinical information routinely available at the initial appearance of IFG. If externally validated, this model could significantly extend our ability to detect PDAs at an earlier stage.
Authors: Karel G M Moons; Andre Pascal Kengne; Mark Woodward; Patrick Royston; Yvonne Vergouwe; Douglas G Altman; Diederick E Grobbee Journal: Heart Date: 2012-03-07 Impact factor: 5.994
Authors: Ben Boursi; Brian Finkelman; Bruce J Giantonio; Kevin Haynes; Anil K Rustgi; Andrew D Rhim; Ronac Mamtani; Yu-Xiao Yang Journal: Gastroenterology Date: 2016-12-05 Impact factor: 22.682
Authors: Rahul Pannala; Jeffery B Leirness; William R Bamlet; Ananda Basu; Gloria M Petersen; Suresh T Chari Journal: Gastroenterology Date: 2008-01-18 Impact factor: 22.682
Authors: Arch G Mainous; Vanessa A Diaz; Sonia Saxena; Richard Baker; Charles J Everett; Richelle J Koopman; Azeem Majeed Journal: J R Soc Med Date: 2006-09 Impact factor: 18.000
Authors: Wansu Chen; Rebecca K Butler; Eva Lustigova; Suresh T Chari; Anirban Maitra; Jo A Rinaudo; Bechien U Wu Journal: J Clin Gastroenterol Date: 2022-04-21 Impact factor: 3.174